Data obtained in our study demonstrated that silencing of Drp1 exerted inhibitory properties in mitochondrial fragmentation to attenuate hypercalcemia-induced neurological impairment in CKD through the inactivation of ROS/HIF-1α/EZH2 axis. Here, DNM1L is linked to hypercalcemia disease.